Shanghai Henlius' IND Application for Cancer Therapy Gains China Approval; Shares Down 3%
MT Newswires Live
Dec 02
Shanghai Henlius Biotech (HKG:2696) said China's National Medical Products Administration has approved its investigational new drug application for HLX37, a humanised anti-PD-L1 and anti-VEGF bispecific antibody, according to a Monday filing.
Shares of the pharmaceutical company were down nearly 3% in Tuesday morning trade.
HLX37, developed in-house, is intended to treat advanced or metastatic solid tumours by simultaneously blocking PD-L1-mediated immunosuppression and VEGF-driven tumour angiogenesis, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.